WO2011084618A3 - Compositions and methods for oral drug delivery - Google Patents
Compositions and methods for oral drug delivery Download PDFInfo
- Publication number
- WO2011084618A3 WO2011084618A3 PCT/US2010/060809 US2010060809W WO2011084618A3 WO 2011084618 A3 WO2011084618 A3 WO 2011084618A3 US 2010060809 W US2010060809 W US 2010060809W WO 2011084618 A3 WO2011084618 A3 WO 2011084618A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methods
- drug delivery
- oral drug
- compositions
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2893—Tablet coating processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012544835A JP2013514976A (en) | 2009-12-16 | 2010-12-16 | Compositions and methods for oral drug delivery |
CA2784120A CA2784120A1 (en) | 2009-12-16 | 2010-12-16 | Compositions and methods for oral drug delivery |
EP10795591A EP2512454A2 (en) | 2009-12-16 | 2010-12-16 | Compositions and methods for oral drug delivery |
AU2010339907A AU2010339907A1 (en) | 2009-12-16 | 2010-12-16 | Compositions and methods for oral drug delivery |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28714609P | 2009-12-16 | 2009-12-16 | |
CN200910201248.3 | 2009-12-16 | ||
CN200910201248.3A CN102100912B (en) | 2009-12-16 | 2009-12-16 | Administration composition and preparation method and using method thereof |
US61/287,146 | 2009-12-16 | ||
CN201010227045.4A CN102335431B (en) | 2010-07-14 | 2010-07-14 | A kind of administration composition and preparation and application thereof |
CN201010227045.4 | 2010-07-14 | ||
US36591610P | 2010-07-20 | 2010-07-20 | |
US61/365,916 | 2010-07-20 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2011084618A2 WO2011084618A2 (en) | 2011-07-14 |
WO2011084618A3 true WO2011084618A3 (en) | 2012-01-19 |
Family
ID=44306059
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2010/060809 WO2011084618A2 (en) | 2009-12-16 | 2010-12-16 | Compositions and methods for oral drug delivery |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP2512454A2 (en) |
JP (1) | JP2013514976A (en) |
AU (1) | AU2010339907A1 (en) |
CA (1) | CA2784120A1 (en) |
WO (1) | WO2011084618A2 (en) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110182985A1 (en) * | 2010-01-28 | 2011-07-28 | Coughlan David C | Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof |
AU2011343190B2 (en) | 2010-12-16 | 2016-12-08 | Novo Nordisk A/S | Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid |
CN106117343B (en) | 2011-04-12 | 2020-11-03 | 诺沃—诺迪斯克有限公司 | Double acylated GLP-1 derivatives |
WO2013012954A2 (en) * | 2011-07-19 | 2013-01-24 | Baxter International Inc. | Resorption enhancers as additives to improve the oral formulation of non-anticoagulant sulfated polysaccharides |
DK2827845T3 (en) | 2012-03-22 | 2019-04-01 | Novo Nordisk As | COMPOSITIONS INCLUDING A PROCEDURE AND PREPARING THEREOF |
US10933120B2 (en) | 2012-03-22 | 2021-03-02 | Novo Nordisk A/S | Compositions of GLP-1 peptides and preparation thereof |
RS64942B1 (en) | 2012-03-22 | 2024-01-31 | Novo Nordisk As | Compositions comprising a delivery agent and preparation thereof |
US9993430B2 (en) | 2012-06-20 | 2018-06-12 | Novo Nordisk A/S | Tablet formulation comprising semaglutide and a delivery agent |
JP2016525524A (en) * | 2013-07-24 | 2016-08-25 | ノヴォ ノルディスク アー/エス | Pharmaceutical composition for oral insulin administration comprising a tablet core and an anionic copolymer coating |
KR101768446B1 (en) * | 2014-03-21 | 2017-08-17 | 애니젠 주식회사 | Novel Exenatide Analogs and Uses thereof |
AU2015258859B2 (en) | 2014-05-15 | 2020-07-23 | Rani Therapeutics, Llc | Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins |
US11548940B2 (en) | 2014-05-15 | 2023-01-10 | Rani Therapeutics, Llc | Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
CN107205949A (en) * | 2015-01-29 | 2017-09-26 | 诺和诺德股份有限公司 | Discharge comprising label and immediately the pharmaceutical composition that oral GLP 1 is administered that is used for being coated |
EP3250191B1 (en) * | 2015-01-29 | 2024-01-17 | Novo Nordisk A/S | Tablets comprising glp-1 agonist and enteric coating |
US20180000742A1 (en) * | 2015-01-29 | 2018-01-04 | Novo Nordisk A/S | Pharmaceutical Composition for Oral Insulin Administration Comprising a Tablet Core and a Polyvinyl Alcohol Coating |
PT3280447T (en) * | 2015-04-08 | 2019-05-14 | Torrent Pharmaceuticals Ltd | Pharmaceutical formulations |
JP7202070B2 (en) * | 2015-05-01 | 2023-01-11 | ラニ セラピューティクス, エルエルシー | Pharmaceutical compositions and methods for fabrication of solid masses containing polypeptides and/or proteins |
CN104998251A (en) * | 2015-07-08 | 2015-10-28 | 哈尔滨吉象隆生物技术有限公司 | Intestinal absorption promoting liraglutide salt for preparing oral enteric-coated preparations |
CN105079793A (en) * | 2015-07-18 | 2015-11-25 | 哈尔滨吉象隆生物技术有限公司 | Liraglutide and metformin hydrochloride compound preparation applicable to oral administration |
CN105079794A (en) * | 2015-07-18 | 2015-11-25 | 哈尔滨吉象隆生物技术有限公司 | Liraglutide and sulfonylurea compound preparation for oral administration |
RU2617049C1 (en) * | 2016-05-12 | 2017-04-19 | Федеральное государственное бюджетное учреждение "Национальный исследовательский центр "Курчатовский институт" | Anticancer drug based on niclosamide |
TWI804571B (en) | 2018-02-02 | 2023-06-11 | 丹麥商諾佛 儂迪克股份有限公司 | Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid |
TWI829687B (en) | 2018-05-07 | 2024-01-21 | 丹麥商諾佛 儂迪克股份有限公司 | Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0454383A1 (en) * | 1990-04-23 | 1991-10-30 | Aicello Chemical Co., Ltd. | Large intestinal dissociative polypeptide series oral formulation |
EP0460921A2 (en) * | 1990-06-04 | 1991-12-11 | Aicello Chemical Company Limited | Large intestinal dissociative hard capsules |
WO1998032426A1 (en) * | 1997-01-29 | 1998-07-30 | Polin Industria Chimica S.P.A. | Time-specific controlled release dosage formulations and method of preparing same |
WO2000041740A2 (en) * | 1999-01-11 | 2000-07-20 | The Regents Of The University Of California | Particles for oral delivery of peptides and proteins |
US20020044975A1 (en) * | 1994-04-22 | 2002-04-18 | Shunsuke Watanabe | Colon-specific drug release system |
WO2005002549A1 (en) * | 2003-07-04 | 2005-01-13 | Nycomed Danmark Aps | Parathyroid hormone (pth) containing pharmaceutical compositions for oral use |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4722941A (en) | 1978-06-07 | 1988-02-02 | Kali-Chemie Pharma Gmbh | Readily absorbable pharmaceutical compositions of per se poorly absorbable pharmacologically active agents and preparation thereof |
US4525339A (en) | 1982-10-15 | 1985-06-25 | Hoffmann-La Roche Inc. | Enteric coated oral dosage form |
US4874795A (en) | 1985-04-02 | 1989-10-17 | Yesair David W | Composition for delivery of orally administered drugs and other substances |
EP0200508B1 (en) | 1985-04-27 | 1991-10-02 | Nitto Denko Corporation | Adhesive oral bandages and oral pharmaceutical preparations |
HU198626B (en) | 1986-05-27 | 1989-11-28 | Sandoz Ag | Process for producing pharmaceutical compositions comprising somatostatin analogues as active ingredient |
US6156731A (en) | 1989-05-10 | 2000-12-05 | G. D. Searle & Co. | Polypeptide composition for oral administration |
JP3249147B2 (en) | 1990-06-01 | 2002-01-21 | キリン−アムジエン・インコーポレーテツド | Oral preparation containing bioactive protein |
US5714167A (en) | 1992-06-15 | 1998-02-03 | Emisphere Technologies, Inc. | Active agent transport systems |
CA2070061C (en) | 1991-06-07 | 2004-02-10 | Shigeyuki Takama | Physiologically active polypeptide-containing pharmaceutical composition |
US5318781A (en) | 1993-04-06 | 1994-06-07 | Hoffmann-La Roche Inc. | Absorption enhancement of antibiotics |
SE9302135D0 (en) | 1993-06-18 | 1993-06-18 | Kabi Pharmacia Ab | NEW PHARMACEUTICAL COMPOSITION |
US5424289A (en) | 1993-07-30 | 1995-06-13 | Alza Corporation | Solid formulations of therapeutic proteins for gastrointestinal delivery |
PT742011E (en) | 1994-11-17 | 2002-10-31 | Toray Industries | PREPARATION THAT MAY BE ABSORBED BY PERCUTANEOUS VIA |
US5827534A (en) | 1995-05-24 | 1998-10-27 | University Of Maryland At Baltimore | Oral dosage composition comprising zonnula occludens toxin and a therapeutic agent for intestinal delivery |
US5817624A (en) | 1995-06-05 | 1998-10-06 | Alza Corporation | Permeation enhancer compositions for increased absorption of therapeutic proteins through the colonic membrane |
GB9516268D0 (en) | 1995-08-08 | 1995-10-11 | Danbiosyst Uk | Compositiion for enhanced uptake of polar drugs from the colon |
CA2184316A1 (en) | 1995-09-12 | 1997-03-13 | Wei-Chi Liao | Buccal delivery system for therapeutic agents |
US5912014A (en) | 1996-03-15 | 1999-06-15 | Unigene Laboratories, Inc. | Oral salmon calcitonin pharmaceutical products |
JP2001503749A (en) | 1996-10-30 | 2001-03-21 | セラテック・インコーポレーテッド | Fatty acid esters of glycolic acid and salts thereof as permeation enhancers |
WO1999001579A1 (en) | 1997-07-01 | 1999-01-14 | Isis Pharmaceuticals, Inc. | Compositions and methods for the delivery of oligonucleotides via the alimentary canal |
US6423334B1 (en) | 1997-10-01 | 2002-07-23 | Elan Corporation, Plc | Composition and method for enhancing transport across gastrointestinal tract cell layers |
JPH11246439A (en) | 1998-03-02 | 1999-09-14 | Hisamitsu Pharmaceut Co Inc | Transmucosal absorption accelerator |
CN1161107C (en) | 1998-11-27 | 2004-08-11 | 高田宽治 | Oral formulation for gastrointestinal drug delivery |
US7658938B2 (en) | 1999-02-22 | 2010-02-09 | Merrion Reasearch III Limited | Solid oral dosage form containing an enhancer |
US20070148228A1 (en) | 1999-02-22 | 2007-06-28 | Merrion Research I Limited | Solid oral dosage form containing an enhancer |
DE60038097T2 (en) | 1999-02-22 | 2009-02-12 | Merrion Research I Ltd. | SOLID ORAL DOSAGE FORM CONTAINING A RESORPTION AMPLIFIER |
US8119159B2 (en) | 1999-02-22 | 2012-02-21 | Merrion Research Iii Limited | Solid oral dosage form containing an enhancer |
US7316819B2 (en) | 2001-03-08 | 2008-01-08 | Unigene Laboratories, Inc. | Oral peptide pharmaceutical dosage form and method of production |
US20030124196A1 (en) | 2001-08-22 | 2003-07-03 | Susan Weinbach | Pulsatile release compositions and methods for enhanced intestinal drug absorption |
US7651694B2 (en) | 2004-02-13 | 2010-01-26 | Nod Pharmaceuticals, Inc. | Therapeutic calcium phosphate particles and methods of making and using same |
PL1773878T3 (en) | 2004-07-19 | 2015-07-31 | Biocon Ltd | Insulin-oligomer conjugates, formulations and uses thereof |
US20060046962A1 (en) | 2004-08-25 | 2006-03-02 | Aegis Therapeutics Llc | Absorption enhancers for drug administration |
US20090087484A1 (en) | 2007-09-28 | 2009-04-02 | Alza Corporation | Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules |
US20090111736A1 (en) | 2007-10-29 | 2009-04-30 | Sri International | Orally-Absorbed Solid Dose Formulation for Vancomycin |
WO2009135190A2 (en) | 2008-05-01 | 2009-11-05 | Nod Pharmaceuticals, Inc. | Therapeutic calcium phosphate particles and methods of making and using same |
-
2010
- 2010-12-16 WO PCT/US2010/060809 patent/WO2011084618A2/en active Application Filing
- 2010-12-16 AU AU2010339907A patent/AU2010339907A1/en not_active Abandoned
- 2010-12-16 CA CA2784120A patent/CA2784120A1/en not_active Abandoned
- 2010-12-16 JP JP2012544835A patent/JP2013514976A/en not_active Withdrawn
- 2010-12-16 EP EP10795591A patent/EP2512454A2/en not_active Withdrawn
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0454383A1 (en) * | 1990-04-23 | 1991-10-30 | Aicello Chemical Co., Ltd. | Large intestinal dissociative polypeptide series oral formulation |
EP0460921A2 (en) * | 1990-06-04 | 1991-12-11 | Aicello Chemical Company Limited | Large intestinal dissociative hard capsules |
US20020044975A1 (en) * | 1994-04-22 | 2002-04-18 | Shunsuke Watanabe | Colon-specific drug release system |
WO1998032426A1 (en) * | 1997-01-29 | 1998-07-30 | Polin Industria Chimica S.P.A. | Time-specific controlled release dosage formulations and method of preparing same |
WO2000041740A2 (en) * | 1999-01-11 | 2000-07-20 | The Regents Of The University Of California | Particles for oral delivery of peptides and proteins |
WO2005002549A1 (en) * | 2003-07-04 | 2005-01-13 | Nycomed Danmark Aps | Parathyroid hormone (pth) containing pharmaceutical compositions for oral use |
Also Published As
Publication number | Publication date |
---|---|
WO2011084618A2 (en) | 2011-07-14 |
CA2784120A1 (en) | 2011-07-14 |
AU2010339907A1 (en) | 2012-07-05 |
EP2512454A2 (en) | 2012-10-24 |
JP2013514976A (en) | 2013-05-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2011084618A3 (en) | Compositions and methods for oral drug delivery | |
WO2009088414A3 (en) | Oral pharmaceutical dosage forms | |
WO2008085765A3 (en) | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain | |
AU2007295179A1 (en) | Dosage unit for sublingual, buccal or oral administration of water-insoluble pharmaceutically active substances | |
WO2008120207A3 (en) | Compositions for nasal delivery | |
WO2009085990A3 (en) | Processes for the preparation of sitagliptin and pharmaceutically acceptable salts thereof | |
WO2008038003A3 (en) | Pharmaceutical compositions of aripiprazole | |
SI2046298T1 (en) | Pharmaceutical dosage form containing pharmaceutically acceptable solubilizing composition | |
MX2020011961A (en) | Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances. | |
WO2006082523A3 (en) | Pharmaceutical sustained release composition of metformin | |
ZA200701576B (en) | Time-limited release type granular pharmaceutical composition for oral administration and intraoral rapid disintegration tablet containing the composition | |
WO2007086078A3 (en) | Novel pharmaceutical compositions and process of preparation thereof | |
MX2010004323A (en) | Oral dosage forms comprising licarbazîpine acetate. | |
WO2010097243A3 (en) | Process for forming solid oral dosage forms of solifenacin and its pharmaceutically acceptable salts | |
WO2012010669A3 (en) | Medicinal drug for oral administration comprising a mixture of silodosin and a basic copolymer | |
WO2009140341A3 (en) | Atorvastatin compositions | |
EP2168586A4 (en) | Active ingredient of a medicinal agent, a medicinal agent, a pharmaceutical composition and method for treating dementia syndrome patients | |
WO2010012459A3 (en) | A process for the preparation of solifenacin salts and their inclusion into pharmaceutical dosage forms | |
WO2008101173A3 (en) | Biodegradable compositions and materials | |
WO2010044097A3 (en) | Novel dosage form of paliperidone and process for preparing the same | |
ATE479427T1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING CANDESARTAN-CILEXETIL | |
WO2010079433A3 (en) | Pharmaceutical composition comprising melogliptin | |
WO2008004100A3 (en) | Therapeutic compounds | |
WO2010137040A3 (en) | Novel pharmaceutical compositions of ranolazine | |
WO2009060064A3 (en) | Pharmaceutical formulations for the oral administration of ppi |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10795591 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2784120 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010795591 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012544835 Country of ref document: JP Ref document number: 2010339907 Country of ref document: AU |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2010339907 Country of ref document: AU Date of ref document: 20101216 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1728/KOLNP/2012 Country of ref document: IN |